Brokers Issue Forecasts for Celldex Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky expects that the biopharmaceutical company will earn ($1.90) per share for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%.

CLDX has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday. Guggenheim raised their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Friday, March 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $66.00.

Celldex Therapeutics Price Performance

CLDX stock opened at $41.21 on Thursday. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18. The firm’s 50-day moving average is $41.71 and its 200 day moving average is $37.03. The company has a market capitalization of $2.30 billion, a PE ratio of -14.16 and a beta of 1.60.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in Celldex Therapeutics by 19.2% in the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after acquiring an additional 1,044,728 shares in the last quarter. Eventide Asset Management LLC raised its position in shares of Celldex Therapeutics by 126.9% during the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after purchasing an additional 2,030,013 shares during the last quarter. Kynam Capital Management LP lifted its stake in Celldex Therapeutics by 23.1% in the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after buying an additional 600,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Celldex Therapeutics by 16.3% in the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock worth $120,817,000 after buying an additional 427,827 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Celldex Therapeutics by 105.3% during the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock worth $109,308,000 after buying an additional 1,413,722 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.